Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
SGLT-2 CRISPR/Cas9 KO Plasmid (m): sc-434235
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SGLT-2 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the SGLT-2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: SGLT-2 Antibody (D-6): sc-393350
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SGLT-2 CRISPR/Cas9 KO Plasmid (m) | sc-434235 | 20 µg | $397.00 |
Overview
Slc5a2 encodes the sodium–glucose cotransporter SGLT-2, a high-capacity transporter that couples Na⁺ gradients to glucose reabsorption across the apical membrane of renal proximal tubule epithelial cells. By regulating transepithelial glucose flux, SGLT-2 influences cellular energy balance and osmotic homeostasis and interfaces with ion transport processes that shape tubular handling of solutes and water. Altered SLC5A2/SGLT-2 activity is linked to dysregulated glucosuria and systemic glucose homeostasis, making it relevant to metabolic phenotypes and renal physiology studies. In mice, Slc5a2 provides a tractable model for interrogating glucose transport mechanisms and renal contributions to metabolic stress responses.
SGLT-2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Slc5a2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Slc5a2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Slc5a2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SGLT-2 protein expression.
This CRISPR knockout system enables efficient generation of Slc5a2-deficient cell models for investigation of SGLT-2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Slc5a2 exon(s) critical for SGLT-2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Slc5a2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by SGLT-2 CRISPR/Cas9 KO Plasmid (m) and SGLT-2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Slc5a2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by SGLT-2 HDR Plasmid (m) and SGLT-2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Slc5a2 homology arms to support homology-directed repair at defined Slc5a2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.